Pre-existing cytotoxic capacity of CD8+and CD4+T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy
Other conference contribution, 2025
Immune checkpoint blockade (ICB) therapy has shown promising activity in Richter Transformation (RT), yet the tumor microenvironmental (TME) determinants of response and resistance to this therapy remain incompletely defined. Our previous single-cell RNA sequencing (scRNA-seq)-based analysis of splenocytes from CLL and RT mouse models identified enrichment in CD8+ effector/exhausted and CD4+ cytotoxic T cells, together with CXCL9/10+ pro-inflammatory macrophages, as a characteristic of most RT cases. The deeper characterization and the functional activities of these candidate cell populations, however, have not yet been elucidated.
Author
Johan Gustafsson
Massachusetts Institute of Technology (MIT)
University of Gothenburg
Chiara Tomasoni
Cornell University
Graydon Moorhead
Broad Institute
Gabriela Brunsting Hoffmann
Dana-Farber Cancer Institute
Erik Landolsi
Chalmers, Electrical Engineering, Signal Processing and Biomedical Engineering
Wesley Lu
Dana-Farber Cancer Institute
Ruitong Li
Broad Institute
Shuqiang Li
Dana-Farber Cancer Institute
Nicholas Haradhvala
Broad Institute
Connor Johnson
Broad Institute
Stephanie Deng
Dana-Farber Cancer Institute
Donna Neuberg
Dana-Farber Cancer Institute
Xia Bu
Dana-Farber Cancer Institute
Gordon Freeman
Dana-Farber Cancer Institute
Othman Al-Sawaf
University Hospital Cologne
University of Cologne
Barbara Eichhorst
University Hospital Cologne
University of Cologne
Erin Parry
Dana-Farber Cancer Institute
Broad Institute
Harvard University
Gad Getz
Massachusetts General Hospital
Broad Institute
Harvard University
Catherine Wu
Harvard University
Dana-Farber Cancer Institute
Broad Institute
Elisa Ten Hacken
Cornell University
Blood
0006-4971 (ISSN) 1528-0020 (eISSN)
Vol. 146 Suppl 1 243-244
67th ASH Annual meeting
Orlando, FL, USA,
Orlando, FL, USA,
Subject Categories (SSIF 2025)
Cell and Molecular Biology
Cancer and Oncology
Immunology in the Medical Area
DOI
10.1182/blood-2025-243